Navigation Links
Haemacure financing receives shareholder consent - Series B Warrants are amended


MONTREAL, May 14 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE) announces that it has obtained the consent required from its shareholders to commence implementing a financing strategy designed to get back into the clinic for the pivotal Phase II/Phase III clinical trials for its next generation, all-human fibrin sealant during Q1-2009. The strategy involves the amendment of the terms and conditions of 62.5 million outstanding Series B common share purchase warrants issued by Haemacure by way of private placement in January 2007.

"I am very pleased with the level of support that our shareholders have demonstrated by approving this amendment to the Series B Warrants, thus enabling Haemacure to finance operations with the least dilution possible", said Mr. Joseph Galli, Chairman & CEO of Haemacure. "Participants in our January 2007 private placement indicated their willingness to further finance the Company based on Haemacure achieving certain value creation milestones. Haemacure is on-time and on budget to meeting the three milestones necessary to getting back into the clinic for its next generation fibrin sealant by Q1-2009. These milestones are the commissioning of the manufacturing facility (IQ/OQ) by mid '08, the production of clinical material by Fall '08, and the approval of an amendment to the IND currently open with the FDA (end '08)", continued Mr. Galli. "Concurrent with our getting back into the clinic with our fibrin sealant, we are working on strategic partnership opportunities that will enable Haemacure to rapidly become a significant player on a global scale" concluded Mr. Galli.

Each of the Series B Warrants currently entitles the holder to acquire one additional common share of Haemacure at a price of $0.20 for a period of five years from the date of issuance. As a result of the amendment, if Series B Warrants are exercised during a period of ten business days commencing on May 29, 2008 and ending on June 12, 2008, Haemacure will issue to the holder, with each Haemacure common share purchased upon the exercise of Series B Warrants, one additional common share purchase warrant. Each additional warrant will entitle the holder to acquire one additional common share of Haemacure at a price of $0.25 until April 18, 2013.

If Series B Warrants are not exercised during the ten business-day period, the holder will not be entitled to receive the additional warrants upon the subsequent exercise of Series B Warrants. Holders of Series B Warrants who do not exercise them during the ten business-day period will retain the right to exercise the Series B Warrants in accordance with their original terms and conditions.

If all of the Series B Warrants are exercised during the ten business-day period, and all of the additional warrants are also exercised, Haemacure will issue a total of 62,500,000 common shares upon the exercise of the additional warrants, representing additional dilution of 38.2% when compared to the 163,800,917 common shares of Haemacure currently issued and outstanding.

The effective date of the amendment will be on the tenth business day after the issuance of this press release. The amendment to the terms and conditions of the Series B Warrants has been approved by the Toronto Stock Exchange, which required that the amendment be approved by Haemacure's shareholders, other than "insiders" of Haemacure who hold Series B Warrants. Haemacure relied on an exemption, set out in section 604(d) of the TSX Company Manual, from the requirement to call a shareholders' meeting to consider the amendment. Pursuant to the exemption, Haemacure provided written evidence to the TSX that holders of more than 50% of Haemacure's common shares (other than "insiders" of Haemacure who hold Series B Warrants) are familiar with the terms of the amendment and in favor of it. A total of nine "insiders" of Haemacure hold Series B Warrants. The Schedule annexed to this press release sets out: (a) the names and positions of the "insiders" who hold Series B Warrants; and (b) assuming such "insiders" exercise all Series B Warrants and additional warrants held by them, the number and percentage of common shares of Haemacure that each will own.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


Number of Percentage

Number of Number of Common of Common

Shares Series B Shares - Shares -

Name of Insider Held / Warrants Post Post

and Position Controlled Held Exercise Exercise

--------------- ---------- --------- --------- ----------

Firebird Global Master

Fund II, Ltd

Holder of more than

10% of outstanding

shares 15,000,000 7,500,000 30,000,000 10.4

Firebird Global Master

Fund, Ltd

Holder of more than 10%

of outstanding shares 10,000,000 5,000,000 20,000,000 6.9

Galli, Joseph

Officer and Director 2,216,300 650,000 3,516,300 1.2

Paquin, Marc

Officer and Director 1,947,000 250,000 2,447,000 0.8

Johnson, Wayne

Director 415,770 175,000 765,770 0.3

Alary, Pierre

Director 314,000 125,000 564,000 0.2

Baehr, Paul

Director 265,000 125,000 515,000 0.2

Lemieux, Gilles

Officer 279,350 25,000 329,350 0.1

Pare, Lyne

Officer 50,000 25,000 100,000 0.03

---------- ------------------------------------

Total 30,620,920 13,875,000 58,370,920 20.2

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
2. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
3. Haemacure Reports on its annual general and special meeting of shareholders
4. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
5. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
6. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
7. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
8. Haemacure Reports Third Quarter 2007 Results
9. InfoLogix Completes $25 Million Senior Debt Financing
10. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
11. Astute Medical Raises $6.2 Million in Series A Financing Round Led by De Novo Ventures
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... ... unique analog distortion effect tool designed specially for Final Cut Pro X. ... limiltess looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is ...
(Date:11/28/2015)... ... , ... Trying to relax on a couch can actually be uncomfortable, so ... design due to personal experience with a bad back," he said. , This easy-to-use, ... well as increases support. It also makes it easier to eat, do other activities ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: